Multivariate analysis of prognostic factors for survival in 44 patients with T-MF
| Characteristics . | Univariate Analysis . | Multivariate Analysis (final model) . | ||
|---|---|---|---|---|
| HR . | P . | HR (95% CI) . | P . | |
| Age | ||||
| Younger than 60 y | 1.00 | 1.00 | ||
| At least 60 y | 2.10 | .11 | 2.81 (1.03-7.61) | .04 |
| Sex | ||||
| Male | 1.00 | |||
| Female | 0.51 | .11 | ||
| Clinical stage | ||||
| IIb | 1.00 | 1.00 | ||
| IV | 1.96 | .10 | 2.22 (0.99-4.98) | .05 |
| Stage of skin disease | ||||
| T2 | 1.00 | |||
| T3 | 0.49 | .26 | ||
| Delay MF/T-MF | ||||
| Less than 2 y | 1.00 | |||
| At least 2 y | 0.62 | .33 | ||
| Extracutaneous spreading (follow-up) | ||||
| Yes | 1.00 | |||
| No | 2.49 | .02 | ||
| % of large cells | ||||
| 25%-49% | 1.00 | |||
| 50%-79% | 0.51 | .32 | ||
| 80%-100% | 0.45 | .25 | ||
| CD30 expression | ||||
| No staining | 1.00 | |||
| Positivity at less than 75% | 0.39 | .14 | ||
| Positivity at 75% or more | 0.43 | .18 | ||
| Characteristics . | Univariate Analysis . | Multivariate Analysis (final model) . | ||
|---|---|---|---|---|
| HR . | P . | HR (95% CI) . | P . | |
| Age | ||||
| Younger than 60 y | 1.00 | 1.00 | ||
| At least 60 y | 2.10 | .11 | 2.81 (1.03-7.61) | .04 |
| Sex | ||||
| Male | 1.00 | |||
| Female | 0.51 | .11 | ||
| Clinical stage | ||||
| IIb | 1.00 | 1.00 | ||
| IV | 1.96 | .10 | 2.22 (0.99-4.98) | .05 |
| Stage of skin disease | ||||
| T2 | 1.00 | |||
| T3 | 0.49 | .26 | ||
| Delay MF/T-MF | ||||
| Less than 2 y | 1.00 | |||
| At least 2 y | 0.62 | .33 | ||
| Extracutaneous spreading (follow-up) | ||||
| Yes | 1.00 | |||
| No | 2.49 | .02 | ||
| % of large cells | ||||
| 25%-49% | 1.00 | |||
| 50%-79% | 0.51 | .32 | ||
| 80%-100% | 0.45 | .25 | ||
| CD30 expression | ||||
| No staining | 1.00 | |||
| Positivity at less than 75% | 0.39 | .14 | ||
| Positivity at 75% or more | 0.43 | .18 | ||
HR = hazard ratio; CI = confidence interval.